Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting

Ovarian cancer (OC) is the eighth most common cancer among the female population and the most lethal of all the female reproductive system malignancies. Poly (ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment scenario of metastatic OC in the maintenance setting post platinum-bas...

Full description

Bibliographic Details
Main Authors: Mauro Francesco Pio Maiorano, Brigida Anna Maiorano, Annalucia Biancofiore, Gennaro Cormio, Evaristo Maiello
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Pharmaceuticals
Subjects:
niraparib (ZEJULA<sup>®</sup>)
PARP
ovarian cancer
BRCA
target therapy
Online Access:https://www.mdpi.com/1424-8247/16/9/1261

Internet

https://www.mdpi.com/1424-8247/16/9/1261

Similar Items